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Background: Radical prostatectomy (RP) is a leading treatment option for localised prostate cancer. Although
hospital in-patient stays accounts for much of the costs of treatment, little is known about population-level trends
in length-of-stay (LOS). We investigated factors predicting hospital LOS and readmissions in men who had RP
following prostate cancer.
Methods: Incident prostate cancers (ICD-O3: C61), diagnosed January 2002-December 2008 in men < 70 years, were
identified from the Irish Cancer Registry, and linked to public hospital episodes. For those who had RP (ICD-9 CM
procedure codes 60.3, 60.4, 60.5, 60.62) the associated hospital episode was identified. LOS was calculated as the
number of days from date of admission to date of discharge. Patient-, tumour-, and health service-related factors
predicting longer LOS (upper quartile, >9 days) were investigated using logistic regression. Patterns in day-case and
in-patient readmissions within 28 days of discharge following RP were explored.
Results: Over the study period 9096 prostate cancers were diagnosed in men under 70, 26.5% of whom had RP by
end of follow-up 31/12/2009. Two of eight public hospitals and eight of forty surgeons carried out 50% of all
public-service RPs. Median LOS was 8 days (10th-90th percentile = 6-13 days) and fell significantly over time (2002,
9 days; 2008, 7 days; p < 0.001). In adjusted analyses men who were not married (OR = 1.71, 95% CI 1.25-2.34), had
co-morbidities (OR = 1.64, 95% CI 1.25-2.16) or stage III-IV cancer (OR = 2.19, 95% CI 1.44-3.34) were significantly
more likely to have prolonged LOS. Those treated in higher volume hospitals (annual median >49 RPs) or by higher
volume surgeons (annual median >17 RPs) were significantly less likely to have prolonged LOS (OR = 0.34, 95% CI
0.26-0.45; OR = 0.55, 95% CI 0.42-0.71 respectively).
Conclusion: Median LOS after RP decreased between 2002 and 2008 in Ireland but it remains higher than in both
England and the US. Although volumes of RPs conducted in Ireland are low, there is considerable variation
between hospitals and surgeons. Hospital and surgeon volume were strong predictors of shorter LOS, after
adjusting for other variables. These factors point to a need for a comprehensive review of prostate cancer service
provision.
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In 2008 prostate cancer was the most common incident
cancer in men in the developed regions of the world; in
Europe it was estimated to account for 21% of all new
cancers diagnosed in men [1]. The increasing incidence
observed over the past two decades in many developed
countries has been attributed to increased detection as a
result of prostate-specific antigen (PSA) testing [2,3].* Correspondence: m.kelly@ncri.ie
National Cancer Registry, Building 6800, Cork Airport Business Park, Cork,
Ireland
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reproduction in any medium, provided the orThe Republic of Ireland (ROI), where PSA testing is
used extensively in primary care [4], was estimated to
have the highest prostate cancer incidence rate in Eur-
ope in 2008 [5]. One of the consequences of this exten-
sive testing is that the profile of prostate cancers is
changing: the age at diagnosis is falling and higher pro-
portions have localised disease [6].
A range of treatment options are available for prostate
cancer, including surgery, radiotherapy and androgen
deprivation therapy. Recent European guidelines on pros-
tate cancer treatment recommend radical prostatectomyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Radical prostatectomy in men aged < 70 years at
diagnosis, 2002–2008, dataset overview.
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of more than 10 years, who accept the risk of treatment-
related complications [7]. In the UK RP use has increased
rapidly in recent years [8,9], and in the US it is now one of
the most common treatment options for localised disease
[10,11].
The costs to health services of treating prostate cancer
are significant and the initial treatment modality affects
both short-term and long-term costs [12]. In 2006, the
mean direct cost per patient for initial treatment was
over €3500 in the UK and Germany, and over €5,000 in
France and Italy [13]. Hospitalisation, both for initial
surgery and for any readmissions during the first year of
care, account for the largest proportion of these costs
[14].
Approaches to RP are evolving rapidly, driven by
technological advances; in addition to conventional open
surgery, the procedure may be done laparoscopically ei-
ther by a surgeon alone, or by a surgeon assisted by a
robot [15]. It has been suggested that different ap-
proaches are associated with variations in post-operative
recovery and length-of stay (LOS) [16]. These develop-
ments might be expected to have impacted on LOS, but
population-level data is limited. It was against this back-
ground that we conducted a population-based analysis




The study setting was Ireland, which has a mixed
public-private health care system. All residents are enti-
tled to use the public health system. Public hospitals also
offer private health care, and patients can opt to transfer
from public to private care at any time. Patients can also
choose to be treated in private hospitals. Thus, there are
three categories of patients: (1) public patients treated
within public hospitals; (2) private patients who pay for
treatment within public hospitals, either out-of-pocket
or through private health insurance; and (3) private pa-
tients who pay for treatment in private hospitals.
Data sources
The primary data sources for this study were the Na-
tional Cancer Registry (NCR) and the Hospital In-
Patient Enquiry Scheme (HIPE). The NCR records
demographic and clinical information for all cancers di-
agnosed in the population usually resident in Ireland
[17]. Treatment received within the first year of diagno-
sis is also collected. Most (97.5%) registrations are made
by tumour registration officers (TROs) who collate and
abstract data from various sources - including pathology
laboratories, radiotherapy clinics, patient administration
systems, and medical records departments - accordingto internationally agreed guidelines. The remaining reg-
istrations are derived from death certificates (2%) and
from general practitioners ( < 0.5%). Death certificates
are provided by the Central Statistics Office [18]; date
and cause of death in cases registered by the NCR are
ascertained by linkage to death certificates using pro-
babilistic matching methods. Completeness of case as-
certainment is estimated to be in excess of 97% [19].
HIPE is a computer-based information system that
collects data on discharges from all acute public hospi-
tals in Ireland [20]. Limited demographic, clinical and
administrative data are collected [21]. Data are subject
to computer-based edits/checks at data entry and later
validation checks [22]. The NCR is provided with all
HIPE records which mention cancer or cancer-related
procedures such as radiotherapy and chemotherapy. Pri-
vate hospitals can volunteer to contribute data to HIPE,
but coverage is incomplete so, in this study information
from HIPE was limited to patients treated in public hos-
pitals (as either public or private patients).
Figure 1 provides an overview of the creation of the
analysis dataset. Prostate cancers (ICD10-O3: C61)
newly diagnosed between 2002 and 2008 were identified
from the NCR. Since RP is rarely conducted in older
men [23], the dataset was then limited to men aged
< 70 years at diagnosis who had a RP (ICD 9 CM pro-
cedure codes 60.3, 60.4, 60.5, 60.62) recorded by the
NCR before the end of follow-up on the 31/12/2009.
Using probabilistic matching techniques, these prostate
cancers were linked to HIPE episodes. We excluded 94
men who had RP in a public hospital but had a previous
diagnosis of cancer; 63 of these 94 men were diagnosed
in the 12 months prior to the prostate cancer diagnosis.
Almost all of the cancers (95%) that occurred in the year
prior to the prostate cancer diagnosis were bladder can-
cer (C67).
Information on patient demographics, clinical and
treatment data and provider volume were derived from
NCR data. Deprivation was measured using an index
Kelly et al. BMC Health Services Research 2013, 13:244 Page 3 of 9
http://www.biomedcentral.com/1472-6963/13/244created from 2002 census variables which is based on
the patient’s area of residence at the time of diagnosis
[24]. Information on tumour grade is routinely recorded
as part of the cancer registration process using the
WHO grading system. Information on Gleason score
(GS) recorded in medical records was translated by
TROs into WHO grading as follows: GS < 5 = grade 1;
GS 5-7 = grade 2; and GS > 7 = grade 3. Stage was de-
fined according to American Joint Committee on Cancer
(AJCC) summary staging [25]. For each hospital the an-
nual volume of RPs performed and the median for the
entire period was determined. Hospitals were classified
as “lower” or “higher” volume by ordering hospitals on
the period median volume and splitting so that approxi-
mately 50% of patients treated fell into each category.
The same approach was used for surgeon volume. Since
surgeons can work in more than one hospital and in pri-
vate and public hospitals, surgeon volume was calculated
from NCR data based on all RPs they performed in ei-
ther public or private hospitals during 2002–2008.
“Higher-volume” was defined as >49 RPs per annum for
hospitals and >17 RPs per annum for surgeons.
Information on LOS, co-morbidities, admission type
(emergency/elective) and discharge status (i.e. whether the
patient was “public” or “private” to the consultant at the
time of discharge) was derived from HIPE. Each admission
(and readmission) was categorised as emergency or
elective according to relevant HIPE codes. A co-morbidity
count for each patient, based on the Elixhauser index
[26] - which was developed to predict a range of outcomes
including length-of-stay - was derived from diagnoses
recorded on HIPE during the index surgery episode; the
prostate cancer diagnosis was disregarded in this calculation.
To determine LOS, HIPE episodes were ordered by
date of admission and overlapping episodes combined.
The date of first surgery recorded by the NCR was
matched to the corresponding HIPE episode to identify
the index surgery episode. LOS was defined as the num-
ber of days between the date of admission and the date
of death or discharge, to either home or another non-
acute care facility (e.g. nursing home). For the LOS ana-
lysis, cases were excluded if they had: no HIPE episode
corresponding to the NCR treatment record; surgery in
private hospitals; or surgery after the censoring date
(31/12/2009) (Figure 1).
Duration of discharge was calculated as number of
days from discharge following the RP to the date of next
admission (if any). Patients whose discharge duration
was ≤28 days were considered readmissions. This period
was chosen for two reasons: firstly, because the 28-day
emergency readmission rate is a key hospital perform-
ance indicator in some healthcare settings [27]; and sec-
ondly because catheters inserted routinely following RP
would be expected to have been removed by this time.Statistical analysis
Characteristics of patients who had RP and those who
did not, and of those who had RP in public and private
hospitals, were compared using chi-square tests. Median
LOS was determined overall and by year. Trends in
LOS by year were examined using the Kruskal-Wallis
equality-of-populations rank test [28] and Cuzick’s non-
parametric test for trend [29].
Since we are not aware of any national, or internation-
ally, agreed definition of prolonged LOS following RP, in
the primary analysis we defined a prolonged hospital stay
as a stay of duration greater than the upper-quartile of
LOS (>9 days). Multivariable logistic regression was used
to identify factors which predicted prolonged LOS. Three
types of variables were considered for inclusion in the
model: socio-demographic (age, marital status, deprivation
index, smoking status at diagnosis, patient status at
discharge); clinical (grade, stage, co-morbidity); and care
(hospital volume, surgeon volume, year of surgery). Four
cases had missing information on marital status and were
excluded entirely from the analysis dataset. Cases with
missing data on other variables (deprivation index (n =
139), smoking status at diagnosis (n = 328), patient status
at discharge (n = 112), grade (n = 43) and stage (n = 1128))
were included as a separate level in the multivariable ana-
lysis (see Additional file 1). Variables were included in the
multivariable model if they were significant (p < 0.05) on
likelihood ratio tests. Model goodness-of-fit was checked
using the Hosmer and Lemeshow test [30].
We tested whether the effect of hospital volume on
prolonged LOS was modified by surgeon volume by
comparing two models: one including an interaction
term between hospital and surgeon volume and one
without this.
As the median (LOS= 8 days) and 75th percentile (LOS =
9 days) differed by only one day we conducted a sensitivity
analyses where we repeated the main analysis using the
90th percentile to define prolonged LOS (>12 days). In a
second sensitivity analysis we used aggregated LOS to de-
fine prolonged LOS. Aggregated LOS was the sum of LOS
for the index RP episode plus all overnight readmissions
occurring with 28 days of discharge from the index epi-
sode; in this analysis prolonged LOS was defined as the
upper-quartile of aggregated LOS for all cases (>10 days).
Readmissions were tabulated by hospital and surgeon
volume; these were further categorized into elective and
emergency admissions. Reasons for readmission were
obtained from HIPE diagnostic codes for the relevant epi-
sodes. All analyses were carried out using Stata 11 [31].
Results
9096 incident prostate cancers were diagnosed in men
aged less than 70 years between 2002 and 2008 of whom
26.5% (n = 2411) had a RP by the end of follow-up at 31/
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pared to men who did not have RP, those who did were
younger and more frequently had low or intermediate
grade disease, were married, resident in less derived
areas and had never smoked (Additional file 2). Two
thirds (n = 1610) of all RPs were done in public hospitals.
Patients treated in a public hospital had a lower mean
age, and a greater proportion lived in a deprived area
and a higher proportion smoked at diagnosis than those
treated in private hospitals (Additional file 2).
The number of hospitals performing RP ranged from
a low of 16 in 2002 (8 public, 8 private) to a high of 20
in 2007 (10 public, 10 private). Half of all RPs carried
out in public hospitals were done in two facilities; the
remainder were carried out in eight institutions. In
these eight hospitals the median volume varied from 1
to 43 RPs per year. In total 49 surgeons performed RP
over the study period; of these, 9 worked in private
hospitals only, 9 worked in both public and private in-
stitutions and 31 worked in public hospitals only. The
number of surgeons performing RP ranged from 20 in
2002 to 27 in 2008 and was highest (n = 33) in 2007.
Eight surgeons performed 50% of all RP done in public
hospitals. Median RP volume per surgeon varied from
1 to 17 per year among lower-volume surgeons (an-




Married 1268 287 (22.6)
Other 263 87 (33.1)
Comorbidity5
None 1127 242 (21.5)
Any 408 133 (32.6)
Stage
Unknown 1128 255 (22.6)
I & II 285 75 (26.3)
III & IV 122 45 (37.0)
Hospital volume6
Higher (>49) 754 126(16.7)
Lower (≤49) 781 249 (31.9)
Surgeon volume7
Higher (>17) 750 161 (21.5)
Lower (≤17) 785 214 (27.3)
1total number of men (N), 2number and % with prolonged LOS (n, %), 3adjusted od
morbidities included in the Elixhauser index on HIPE record relating to the RP episo
of RPs performed by surgeon per year in public and private hospitals.
* Variables tested, but not significantly associated with prolonged LOS, and exclude
deprivation index of area of residence, grade/Gleason score and patient status at d
these variables.among higher-volume surgeons (annual median >17
RPs).
Just over 95% (n = 1535) of the men who had RP in a
public hospital had a relevant HIPE episode (Figure 1).
For these men, median LOS was 8 days (10th/90th per-
centiles = 6/13 days; 25th/75th percentiles = 7/9 days).
This decreased significantly from 9 days (10th/90th per-
centiles = 6/15 days) in 2002 to 7 days (10th/90th per-
centiles = 6/12) in 2008 (non-parametric test for trend,
p < 0.001). Median pre-surgery LOS was 1 day (10th/
90th percentiles = 1/2 days) while median post-surgery
LOS was 6 days (10th/90th percentiles = 4/11 days).
In multivariable analysis patients who were not mar-
ried (OR = 1.71, 95% CI 1.25-2.34,), had co-morbidities
(OR 1.64, 95% CI 1.25-2.16), or had later stage disease
(OR = 2.19, 95% CI 1.44-3.34) were significantly more
likely to have a prolonged LOS (upper quartile of LOS
>9 days) (Table 1; results for all variables are shown in
Additional file 1). Patients treated in higher volume hos-
pitals were significantly less likely to have a prolonged
LOS (OR = 0.34, 95% CI 0.26-0.45), as were patients
treated by higher volume surgeons (OR = 0.55, 95% CI
0.42-0.71). There was no evidence of an interaction be-
tween hospital and surgeon volume (Table 2).
One patient died in hospital during the index RP epi-
sode and two men died within 28 days of discharge. Ofn prostate cancer patients undergoing RP in public
LOS > 9 days
Adjusted OR3 95% CI p-value4
1.00 - p < 0.001
1.71 1.25-2.34
1.00 - p < 0.001
1.64 1.25-2.16
1.00 - p < 0.001
1.38 0.99-1.92
2.19 1.44-3.34
0.34 0.26-0.45 p < 0.001
1.00 -
0.55 0.42-0.71 p < 0.001
1.00 -
ds ratios (OR) with 95% confidence intervals (CI) and 4p-values, 5count of
de, 6median number of RPs performed at hospital per year, 7median number
d from the final model: age at diagnosis, smoking status at diagnosis, and
ischarge (public/private to the consultant). See Additional file 1 for the ORs for
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28 days, and just under 6% of all readmissions were
emergencies (Table 3). In total 47 men were readmitted
as emergencies within 28 days. In those men who had a
prolonged LOS (>9 days) at the index episode 4.0% were
readmitted as emergencies within 28 days (that is 15
emergency readmissions out of 375 men with prolonged
LOS at the index episode). In those whose LOS was
≤ 9 days at the index episode 2.8% were readmitted as
emergencies within 28 days (that is 32 emergency
readmissions out of 1160 men). These two proportions
were not significantly different (z = 1.21, p = 0.225).
Readmissions of any type, and overnight admissions,
were more frequent in higher volume hospitals and for
higher volume surgeons (Table 3). Catheter removal and
urine flow study were the two most common procedures
for elective readmission. The most common procedures
for emergency readmission were catheter removal, tom-
ography of abdomen, injection of antibiotics or anti-
coagulants, and endoscopic lavage of blood clots from
bladder.
In the sensitivity analysis using the 90th percentile to
define prolonged LOS (>12 days), 161 men stayed in
hospital for more than 12 days. The factors which sig-
nificantly predicted longer LOS were the same as in the
primary analysis. The effects for all variables were in the
same direction as in the primary analysis. The risk esti-
mates for marital status and surgeon volume were
slightly further from unity than in the primary analysis
(OR not married vs married = 2.13, 95% CI 1.43-3.20;
OR higher vs lower surgeon volume = 0.37, 95% CI 0.25-
0.54); risk estimates for other variables were very similar
to those obtained in the primary analysis (data not
shown).
For the sensitivity analysis using aggregated LOS (LOS
from the index episode plus any overnight stays within
28 days), median LOS during 2002–2008 was 8 days (10th/Table 2 Risk estimates from alternative models for associatio
prolonged LOS
Model Variable (c
Model 1 (primary analysis): Hospital and surgeon
volume both fitted in model (without interaction term)1
Hospital vo
Surgeon vo
Model 2: Surgeon volume omitted Hospital vo
Model 3: Hospital volume omitted Surgeon vo






1Final multivariate model as shown in Table 1, 295% confidence intervals, 3p-value f
baseline model with the addition of an interaction term; the p value is for the inter90th percentiles = 6/14 days; 25th/75th percentiles = 7/
10 days). Median aggregated LOS decreased significantly
from 11 days (IQR 9–14) in 2002 to 8 days (IQR 7–9) in
2008, (non-parametric test for trend, p < 0.001). Factors
which significantly predicted prolonged aggregated LOS
(upper quartile, >10 days) were the same as in the primary
analysis (data not shown).
Discussion
Strengths and limitations
One of the major strengths of this study is that it is
based on high-quality, population-based, cancer registra-
tion data (rather than hospital admission data alone),
providing confidence that the patients included had
prostate cancer. In addition, in our mixed public-private
setting, where clinicians frequently work in both sectors,
the availability of national cancer registry data made it
possible to accurately quantify the entire (i.e. public and
private) volume of cases for each surgeon.
Two thirds of men had RP in a public hospital and
one third in a private hospital. Just over 4% of publicly-
treated patients had no matching HIPE episode. A fail-
ure to find a match between cancer registrations and
hospital episodes can occur for a number of reasons in-
cluding: an inability to match records belonging to the
same person due to typographical errors or missing in-
formation on either system, or no mention of cancer (or
cancer-related procedures) on HIPE, in which case the
episodes would not be available to the cancer registry.
The missing episodes were distributed across hospitals
and years.
We excluded 94 men who had another invasive cancer
diagnosis (other than a non-melanoma skin cancer)
prior to the prostate cancer diagnosis. The majority of
these (67%) were diagnosed in the 12 months prior to
the prostate cancer diagnosis. The diagnosis and treat-
ment of recent previous cancers are likely to have anns between hospital and surgeon volume and
omparison) Adjusted OR1 95% CI2 p-value
lume: (higher vs lower) 0.34 0.26-0.45
lume: (higher vs lower) 0.55 0.42-0.71
lume: (higher vs lower) 0.37 0.29-0.48 p < 0.0013
lume: (higher vs lower) 0.63 0.49-0.81 p < 0.0013
lume main effect: (higher vs lower) 0.28 0.20-0.40 p = 0.1054
lume main effect: (higher vs 0.46 0.33-0.64
effect 1.55 0.92-2.65
or likelihood ratio tests compared to baseline model (model 1), 4Model 4 is the
action term.
Table 3 Readmissions within 28 days of discharge following RP in public hospitals by provider volume
All Hospital volume1 Surgeon volume2
Volume N (%) Lower Higher Lower Higher
Number of RPs 1535 781 754 785 750
Number of readmissions* 854 344 510 373 481
(% of all RPs) 55.6% 22.4% 33.2% 24.3% 31.3%
Readmission type
Elective - day cases 304 228 76 203 101
(% of all readmissions) 35.6% 26.7% 8.9% 23.8% 11.8%
Elective - overnight 503 99 404 145 358
(% of all readmissions) 58.9% 11.6% 53.6% 17.0% 41.9%
Emergency 47 17 30 25 22
(% of all readmissions) 5.5% 2.0% 3.5% 2.9% 2.6%
*excludes those who died at time of index procedure RP (n = 1) or within 28 days of discharge (n = 2), 1higher-volume hospitals are those where >49 RPs were
performed per year during 2002–2008, 2higher-volume surgeons are those who performed >17 RPs per year during 2002–2008.
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cer and hence may impact on LOS in men undergoing
RP. This exclusion means that our results are
generalizable to the population of men treated with RP
for whom prostate cancer is their first cancer.
Comparisons in LOS between countries
Our median LOS of 7 days in 2008 is slightly higher
than reported in England (median 6 days, based on pa-
tients treated in the publically-funded NHS) [9]. Our
median post-operative stay was 6 days and is double that
reported in the US (post-operative stay 3 days in patients
treated through the Medicare health insurance pro-
gramme) [10]. Our analysis of LOS was confined to men
treated in public hospitals only and those treated in pub-
lic and private hospitals differed in terms of age, smok-
ing status and deprivation category. Although none
of these factors were significantly associated with pro-
longed LOS, it is possible that men treated privately
might differ from those treated publicly in other ways
that do impact LOS. For example, men treated privately
might have fewer or less important co-morbidities or be
fit for surgery. Therefore, our results confined to public
patients could over-represent sicker or less fit patients
or those with more complex disease, therefore driving
up median LOS. It is impossible to assess whether this is
true, however, since there are no data available on
comorbidities, fitness for surgery, or case complexity in
private patients.
In the US there has been a concerted effort to reduce
post-surgery LOS following RP using collaborative care
pathways [32-34]. Further reductions have been driven
by increased use of laparoscopic (LRP) and robot
assisted RP (RARP) [10]. Unfortunately we did not have
information on the type of RP conducted and so could
not investigate the impact of these further. However,RARP was not available in public hospitals during the
study period. It is not particularly usual for public hospi-
tals in Ireland to document local guidelines for practice,
so we would expect that most hospitals would not have
established standard post-operative care pathways. Nor
has there been any specific national initiatives to reduce
LOS during the study period. This, together with differ-
ences in casemix, type of procedure performed and pub-
lic and private healthcare cultures, probably explains the
higher LOS in Ireland than in the US.
Time trends in LOS
There was a modest downward trend in median LOS
over the study period, similar to patterns reported else-
where. In England, for example, Hanchanale et al. [9]
reported a decrease in median LOS from 8 days (IQR,
7–10) in 1998 to 6 days (IQR, 5–8) in 2004. The authors
reported a modest increase in the use of LRP but this
accounted for only 4% of RP cases overall and was con-
sidered unlikely to fully explain the downward trend.
A range of national clinical initiatives to improve pa-
tient care post-surgery and reduce LOS are only cur-
rently being developed in Ireland [35] so cannot have
impacted on our study results. However there may have
been local initiatives of which we were not aware. Other
possible – and plausible – explanations for the observed
trend are greater surgical experience resulting from the
increased volume of RPs carried out, together with im-
provements in anaesthetic techniques leading to faster
post-operative recovery times [36].
Factors associated with prolonged LOS
In the adjusted analysis men who were not married, and
who had co-morbidities or later stage disease were sig-
nificantly more likely to have a prolonged hospital stay
(>9 days). We found similar associations in patients with
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servation that married patients have shorter LOS may
reflect a lack of social support among unmarried pa-
tients [38,39]. Urologists may be reluctant to discharge
men who have no identifiable family caregiver. A short-
age of step-down beds could exacerbate this problem as
patients may occupy hospital beds for longer than re-
quired [40]. It might be expected a priori that those with
co-morbidities would have longer LOS; these patients
may need more investigation and work-up before sur-
gery or a longer recovery time post-surgery. Similarly pa-
tients with more advanced disease are likely to need
more investigation and work-up before surgery, more
extensive surgery and more investigation post-surgery to
classify surgical margins and to be assessed for further
treatment.
The observed associations between LOS and provider
volume have been previously reported [32]. What seems
to be uncertain is whether surgeon or hospital volume,
or both, is important. Like us, in an analysis of NHS data
in England, Hanchanale et al. [9] found both hospital
and surgeon volume were inversely associated with LOS.
However, Judge et al. [8], using the same source data,
found that trust volume alone was important. The need
for minimum volume thresholds for urological cancer
surgery has been recognised by surgeons [41] and in
England the National Institute for Clinical Excellence
(NICE) recommends that RP should be provided by
specialised teams typically carrying out 50 or more oper-
ations per annum [42]. In Ireland only two public hospi-
tals conducted 50 or more RPs per year. Evidence also
suggests that experience in a particular mode of RP (i.e.
ORP, LRP, RARP) is important for improved patient out-
comes [41,43,44].
Although we found that both hospital and surgeon
volume were statistically independent predictors of LOS,
in practice these are likely to be related; higher volume
centres are more likely to have more experienced sur-
geons who in turn may drive quality improvements or
improvements in perioperative care. However, higher-
volume centres may also deal with more complex cases
which cannot be adjusted for fully, using simple co-
morbidity counts [45]. Unfortunately we do not have in-
formation on other predictors of case complexity (e.g.
frailty), and so we may have underestimated the strength
of association between higher volume and lower LOS.
Readmissions
There was a high rate of overnight elective readmissions
following RP and, in further analysis, wide variations
between public hospitals were evident. Some private
hospitals in Ireland have a stated policy of overnight re-
admission for catheter removal and it is reasonable to
assume that public hospitals with high overnight electivereadmission rates have a similar policy. The cost-benefit
implications for the health services nationally (and for
individual hospitals) of overnight readmission versus
elective day-patient care for catheter removal are unclear
and warrant further investigation.
Although higher-volume hospitals had a higher over-
night elective readmission rate than lower-volume hospi-
tals, the risk of prolonged LOS remained lower in
higher-volume hospitals when aggregated LOS (i.e. the
sum of LOS for the RP itself and any readmissions
within 28 days), rather than the surgery episode LOS,
was considered. Although the overall numbers were low,
and so need to be interpreted with caution, the data sug-
gested that higher-volume hospitals had more emer-
gency readmissions than lower-volume hospitals; this is
probably a reflection of more complex cases being
treated at higher-volume hospitals.
Centralisation
In comparison with the UK and US the total number
of RPs undertaken in Ireland is small. In addition, the
pool of hospitals and surgeons providing the service
is small and this is further complicated by the
public/private divide. The fact that 50% of RPs in pub-
lic hospitals were carried out at two hospitals (and by
eight urologists) demonstrates the diffusion of cancer
services in Ireland. The National Cancer Control
Programme (NCCP) has embarked on a programme
of centralization of public cancer services. Greater
centralization of prostate cancer services could facili-
tate the development of a pool of experienced sur-
geons potentially leading to a more robust service less
sensitive to loss of personnel and better equipped to
implement technological advances in RP surgery such
as LRP and RARP. It would facilitate the implementa-
tion of clinical initiatives already shown elsewhere to
improve patient and hospital-related outcomes (e.g.
standardized critical care pathways) and – as sug-
gested by this study – lead to shorter LOS. It would
also enable investigation of other aspects of service
provision that could both improve quality-of-care and
might reduce costs (e.g. more efficient discharge pol-
icies and standardised follow-up care). However, cen-
tralisation would be likely to mean that patients would
need to travel further to access care causing increased
inconvenience and cost and, perhaps, impacting on
their satisfaction with care. The relationship between
these factors is complex, and a full analysis of cost and
benefits is required.
Conclusion
Median LOS after RP decreased between 2002 and 2008
in Ireland but it remains higher than in both England and
the US. Although volumes of RPs conducted in Ireland are
Kelly et al. BMC Health Services Research 2013, 13:244 Page 8 of 9
http://www.biomedcentral.com/1472-6963/13/244low, there is considerable variation between hospitals and
surgeons. Hospital and surgeon volume were strong pre-
dictors of shorter LOS, after adjusting for other variables.
These factors point to the need for a comprehensive re-
view of prostate cancer service provision.
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